Overview

A Study of Etripamil in Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are as below: Primary: ·To evaluate the pharmacokinetics (PK) of Etripamil in healthy adult Chinese subjects Secondary: - To evaluate the pharmacodynamics (PD) of Etripamil in healthy adult Chinese subjects - To evaluate the safety and tolerability of Etripamil in healthy adult Chinese subjects Exploratory: ·To evaluate the PK exposure-PD response relationship of etripamil in healthy adult Chinese subjects
Phase:
Phase 1
Details
Lead Sponsor:
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.
Collaborator:
Milestone Pharmaceuticals Inc.
Treatments:
Etripamil